A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting.

ABSTRACT: Immune checkpoint inhibitors (ICIs) are changing all aspects of malignant tumour therapy as an immunotherapy subverter in oncology. However, the current ICIs might induce systemic immune activation in other tissues and organs since they are not tumour-specific, causing the immune system to attack some normal tissues and organs of the human body. The toxicity can also amplify greatly although combined immunotherapy for cancer has increased the curative efficacy. The LC4 peptide was modified to improve its tumour-targeting ability and reduce peripheral immune system activation, which was obtained through phage display peptide library screening and could block the CTLA-4/CD80 interaction. The LC4 peptide as a result, like other ICIs, exerts anti-tumour effects by refreshing T cell function, a

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC9532478 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature